US surgeons have given new tailwind to xenotransplantation after successfully implanting a pig’s heart in a human. The breakthrough not only gives hope to the hundreds of patients who die annually for lack of a doner organ, but also to health care R&D departments who see the therapeutic value of transplanted tissues in tackling neurodegenerative disorders and diabetes.
An organ preservation system from Swedish medical technology company Xvivo played a key role in the first successful transplant of a pig heart into a human patient.
Pig hearts are used in cardiovascular research because their anatomical similarities to human hearts allow blood to flow in the...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
